SARS-CoV-2 Antibody Assays

SARS-CoV-2 Neutralizing Antibody ELISA Kit:

Evaluation of immune response after COVID-19 vaccination and infection.

  • Quantitative, high throughput analysis for neutralizing antibodies in blood samples.
  • Particularly suitable for determining the neutralizing antibody titer after COVID-19 vaccination.
  • Neutralizing antibodies resulting from vaccination blocks the invasion of virus into host cells.
  • The ELISA specifically quantifies the neutralizing antibody titer of those antibodies, which will:
    • Block the receptor-binding domain (RBD) of the S1 subunit of virus’ Spike protein.
    • Thereby preventing the S1-RBD attachment to the human host cell ACE2 receptor.

  • This is achieved in a 1-step competitive ELISA based on:

    • ELISA-wells precoated with S1-RBD
    • Simultaneous competitive incubation of blood sample (antibodies) and peroxidase-labeled ACE-2

  • It takes little manual labor to analyze hundreds of samples in one run.

  • Clinically documented, CE-IVD marked ELISA kit including all necessary reagents.
Contact us

1-step competitive ELISA

The Solsten SARS-CoV-2 Neutralizing Antibody ELISA Kit is a useful tool for quantifying the individual, time-dependent response to vaccination with COVID-19 vaccines from Pfizer-Biontech, Moderna, Astra Zeneca and Johnson&Johnson. Reference: Finalized study per January 11, 2022 at Solsten Diagnostics.

 

The Solsten SARS-CoV-2 Neutralizing Antibody ELISA is a 1-step competitive assay, where neutralizing antibodies in the blood sample competes with the peroxidase-labeled human ACE-2 receptor to bind to the immobilized receptor-binding domain of the virus’ Spike protein (S1-RBD). The reduction in color signal is proportional to the antibody-derived protection (titer) against the virus.

SARS-CoV-2 S&N-IgM/IgG Antibody Rapid Test (Colorimetric)

The SARS-CoV-2 S&N-IgM/IgG Antibody Rapid Test is done is in 10 minutes, and the optional two bands for IgG and IgM antibodies against the SARS-CoV-2 spike or nucleocapsid antigens are read easily by eye. Though the test is qualitative, the intensity of the IgG-band indicates the titer of the blood sample (according to comparisons with ELISA quantification, see graph below).

  • Easy-to-use Rapid Test for IgG and IgM antibodies reacting with antigens (N and S) of SARS-CoV-2.
  • Apply one drop of blood (fingerprick full blood or serum/plasma from venous blood sample).
  • Results in 10 minutes and qualitative reading by eye (pregnancy-test like output).
  • Clinically documented, CE-IVD marked Quick test kit for immediate use.
Each of 273 plasma samples from COVID-19 vaccinated and/or infected individuals was analyzed by the colorimetric SARS-CoV-2 S&N-IgM/IgG Antibody Rapid Test, and the staining intensity of the IgG band was registered subjectively and independently by two experienced operators on an ordinal scale with six scores from 0 (no visible band) to 5 (very intense band). The mean intensity score of each sample was correlated with its titer according to the SARS-CoV-2 Neutralizing Antibody ELISA.
Contact us

The SARS-CoV-2 S Antibody Quantitative Rapid Test

The SARS-CoV-2 S Antibody Quantitative Rapid Test is done in 15 minutes, and the titer of antibodies against the Spike (S) protein of SARS-CoV-2 is measured as a fluorescence signal by the Fluorescence Immunoassay Analyzer

  • Easy-to-use Quantitative Rapid Test for antibodies reacting with the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2.
  • Use one drop of blood (20 µl of fingerprick full blood or 10 µl of serum/plasma from a venous blood sample).
  • The result is achieved in 15 minutes including quantitative reading in 20 seconds by the Fluorescence Immunoassay Analyzer Instrument.
  • Clinically documented, CE-IVD marked quantitative rapid test (see correlation to ELISA results below).
  • Reading of test result requires the Fluorescence Immunoassay Analyzer Instrument
  • Read about the instrument
A high correlation was observed, when the antibody titres of 273 plasma samples from COVID-19 vaccinated and/or infected individuals were determined by the SARS-CoV-2 S Antibody Quantitative Rapid test and the SARS-CoV-2 Neutralizing Antibody ELISA.
Contact us